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Colorectal cancerDown-regulation of hMSH3 is associated with elevated microsatellite alterations at selected tetranucleotide
repeats and low levels of microsatellite instability in colorectal cancer (CRC). However, the mechanism
that down-regulates hMSH3 in CRC is not known. In this study, a signiﬁcant association between over-
expression of glucose transporter 1, a marker for hypoxia, and down-regulation of hMSH3 in CRC tissues
was observed. Therefore, we examined the effect of hypoxia on the expression of hMSH3 in human cell
lines. When cells with wild type p53 (wt-p53) were exposed to hypoxia, rapid down-regulation of both
hMSH2 and hMSH3 occurred. In contrast, when null or mutated p53 (null/mut-p53) cells were exposed to
hypoxia, only hMSH3 was down-regulated, and at slower rate than wt-p53 cells. Using a reporter assay, we
found that disruption of the two putative hypoxia response elements (HREs) located within the promoter re-
gion of the hMSH3 abrogated the suppressive effect of hypoxia on reporter activity regardless of p53 status. In
an EMSA, two different forms of HIF-1α complexes that speciﬁcally bind to these HREs were detected. A larg-
er complex containing HIF-1α predominantly bound to the HREs in hypoxic null/mut-p53 cells whereas a
smaller complex predominated in wt-p53 cells. Finally, HIF-1α knockdown by siRNA signiﬁcantly inhibited
down-regulation of hMSH3 by hypoxia in both wt-p53 and mut-p53 cells. Taken together, our results suggest
that the binding of HIF-1α complexes to HRE sites is necessary for down-regulation of hMSH3 in both wt-p53
and mut-p53 cells.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The DNA mismatch repair (MMR) system contributes to genetic
stability by correcting errors during DNA synthesis, preventing
improper recombination, and participating in cellular events induced
by DNA damaging agents (reviews in [1–3]). An individual who is a
carrier of germline mutations in MMR genes, such as the human
MutL homolog 1 (hMLH1) or human MutS homolog 2 (hMSH2), will
be predisposed to Lynch syndrome. Epigenetic silencing of hMLH1 is
observed in a fraction of sporadic colorectal cancer (CRC) with high
levels of microsatellite instability (MSI-H) [4–6]. In sporadic CRC,
some tumors exhibit low levels of MSI (MSI-L) [6] and/or elevated
microsatellite alterations at selected tetranucleotide repeats (EMAST)
[7]. EMAST has been reported at varying frequencies in a variety of can-
cers including non-small cell lung cancer (NSCLC) [7,8], cancers of theular Biology, Toho University
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rights reserved.head and neck [8], bladder [8–10], kidney [8], non-melanoma skin [9],
prostate [11], serous ovarian [12] and colon and rectal [13–16]. We
previously demonstrated that EMAST is exhibited by 50% to 60% of pri-
mary sporadic CRC [13,14] and loss of the human MutS homolog 3
(hMSH3) results in EMAST andMSI-L in CRC cell lines [13]. Furthermore,
EMAST and MSI-L are signiﬁcantly associated with down-regulation of
hMSH3 in CRC tissues [13,15]. However, the mechanism(s) by which
hMSH3 in CRC tissues are down-regulated is not known. Because
hypoxia is common in solid tumor tissues [17] and it induces down-
regulation of MMR genes in tissue-cultured cell lines, including hMLH1
[18], hMSH2 [19], hMSH6 [19] and hMSH3 [20], it was hypothesized
that hypoxia could be one suchmechanism. In this study, we ﬁrst exam-
ined the expression of glucose transporter 1 (GLUT1), a marker for hyp-
oxia [21], and determined its relationship to hMSH3 expression and
EMAST in CRC tissues. We then investigated the effect of hypoxia on
hMSH3 gene expression at mRNA and protein levels in cultured human
cell lines derived fromCRC and other origins. To understand howhypox-
ia modulates hMSH3 expression, we cloned the promoter region of
hMSH3 and identiﬁed critical regions for the transcription of hMSH3 in
response to hypoxia. Our results show that hypoxia down-regulates
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CRC tissues is likely caused by hypoxia which may result in EMAST and
MSI-L.2. Materials and methods
2.1. CRC tissue samples and immunohistochemistry (IHC)
Twenty-six randomly selected sporadic CRCs were collected from
patients treated at Toho University's Ohmori Hospital (Tokyo) and
two CRC tissues were collected at the University of California San
Diego under IRB approval. The level of hMSH3 expression and the MSI
status of these tissues have been previously described [13,14,22].
Parafﬁn-embedded tissues were deparafﬁnized and rehydrated, fol-
lowed by antigen retrieval (121 °C for 15 min in 0.01 M citrate buffer,
pH 6.0). The tissues were incubated with an anti GLUT1 mouse mono-
clonal antibody (LAB VISION, Fremont, CA) overnight at 4 °C, followed
by treatment with a secondary antibody. Staining was developed by
diaminobenzide chromogen and counterstained with hematoxylin.
The brown and blue signals indicate the presence (brown) or absence
(blue) of GLUT1 immunoreactivity. The expression of GLUT1was scored
at three levels: when GLUT1 protein was detected in more than 50% of
the tumor tissue area, we scored it over-expression (++); when sig-
nals were detected in less than 50% of area, we scored it positive (+);
and when signals were not detected in most of the tumor tissues or
were detected only sporadically within a tissue, we scored it positive/
negative (+/−).2.2. Cells and cell culture
The human CRC cell lines SW480 and SW620, and the human cervi-
cal cancer cell line HeLa S3 were obtained from American Type Culture
Collection (Rockville, MD). The human CRC cell line colo320DMand the
human neuroblastoma cell lines, GOTO and TGW, were obtained from
the Japanese Cell Resources Bank (Osaka). The human embryonic
kidney (HEK) 293 cell line and the human breast adenocarcinoma cell
line MCF-7 were provided by Akimitsu Takagi of the Yakult Central In-
stitute (Tokyo). HCT116+5 and HCT116+3+5 were established as
described [13,23]. p53 knockout HCT116 (null-p53 HCT116) [24] was
provided by Bert Vogelstein. p53 knockout HCT116 with wild type
hMSH3 (null-p53 HCT116+5) was constructed by the transfer of nor-
mal human chromosome 5 to null-p53 HCT116 via micro-cell fusion
[25]. Cells were grown in minimum essential medium (MEM) or RPMI
1640 medium supplemented with 10% fetal bovine serum at 37 °C in
5% CO2 in air in a humidiﬁed atmosphere. In hypoxia, cells were cul-
tured in 5% CO2 in 0.1% O2, where the O2 concentration was controlled
by Pro:ox model 110 (BioSopherix, New York, NY). The cells were con-
tinuously treated by hypoxia until they were harvested for the next
experiments.2.3. Quantitative reverse-transcription polymerase chain
reaction (qRT-PCR)
mRNA was quantiﬁed by qRT-PCR. Exponentially growing cells at
the initial density of 1×106 were cultured in a 10-cm dish at 37 °C.
After 48 hrs, the dish was placed in a normoxic or hypoxic (0.1% O2)
chamber. Total RNA was extracted by the RNeasy Mini kit (Qiagen,
Germantown, MD), and the Takara one step SYBR primescript plus
RT-PCR kit (Takara Bio Co., Otsu, Shiga, Japan) was used for the subse-
quent cDNA synthesis and RT-PCR reactions. Each sample was ampli-
ﬁed in triplicate and analyzed by the Applied Biosystems 7500 Fast
Realtime PCR system (Life Technologies Inc., Carlsbad, CA). For nor-
malization, ribosomal 18S was used [26]. The primer sequences
used in this study are listed in Supplementary Table 1.2.4. Western blotting
Cells at an initial cell density of 1×106 cells per 10-cm dish were
cultured for 2 days in normoxia and then in hypoxia (0.1% O2). After
the indicated days of hypoxia, cells were harvested, cell lysate was pre-
pared and Western blotting analysis was performed as described [27].
Heat-denatured cell lysates were applied and separated on a sodium
dodecylsulfate (SDS)-polyacrylamide gel. Mouse monoclonal anti-
bodies against hMSH3 (BD Biosciences, San Jose, CA), hMSH2 (SAD4)
[28], and hypoxia-inducible factor (HIF)-1α (BD Biosciences) were
used as the primary antibodies to detect each protein. α-tubulin was
used as a loading control and detected by amousemonoclonal antibody
againstα-tubulin (Sigma-Aldrich, St. Louis,MO). The blots were treated
with the ECL-plus system (Amersham Pharmacia Biotech, Inc.) and sep-
arated proteins were visualized and quantiﬁed by a luminescent image
analyzer, LAS-1000plus (Fuji Film Co., Tokyo).
2.5. Transfection of a p53 expression plasmid
Exponentially growing cells at the initial cell density of 2×105 cells/
well in a 6-well plate were cultured for 48 hrs and were transfected
with 1 μg of pCEP4 or a p53 expressing plasmid, pXZ53WT constructed
from pCEP4 [29] using lipofectin (Invitrogen, Life Technologies Inc.,
Carlsbad, CA). After 16 hrs, cultures were replaced with fresh medium
and incubated for an additional 24 hrs. The cells were then cultured
for another 48 hrs in normoxia or hypoxia.
2.6. Reporter gene plasmids and luciferase assay
Reporter plasmids with various DNA fragments spanning from
−3102 to +50 relative to the transcription initiation site of the hMSH3
gene were constructed. Each fragment was ampliﬁed from the genomic
DNA by PCR. Primer sequences have been listed in Supplementary
Table 2. PCR products were ligated into the pGL3-Basic vector (Promega
Co., Madison, WI). Three hypoxia response element (HRE) mutant plas-
mids were constructed using a Takara primeSTAR mutagenesis basal kit
(Takara Bio Co.). The sequence of the ﬁrstHRE1 (GCGTG)wasmutated to
GCATA and the second HRE2 (ACGTG) was mutated to TTTTG. All inserts
and mutations were veriﬁed by DNA sequencing. Luciferase activities
were measured as described [29]. All reporter assays were done in
triplicate.
2.7. RNA interference
Cells (3×105 cells/well) were cultured for 24 hrs in a 6-well plate
and were transfected with 150 pmoles of small interfering RNA
(siRNA) oligomer (Invitrogen) for HIF-1α (5′-AGUUAGUUCAAACUGA
GUUAAUCCC-3′) or a negative control RNA oligomer (Negative Univer-
sal Control Low #3, Invitrogen) using lipofectamin 2000 (Invirogen).
After transfection, cells were cultured in normoxia for 24 hrs and then
placed under normoxia or hypoxia.
2.8. Electrophoretic mobility shift assay (EMSA)
EMSAwas performed as described previously [30]. Brieﬂy, double-
strand oligonucleotide probes (Supplementary Table 3) were pre-
pared with T4 polynucleotide kinase and [γ-32P]-ATP. Nuclear extract
(12 μg) was pre-incubated with 0.1 μg poly[dI–dC]•poly[dI–dC]
(Sigma Chemical Co., St. Louis, MO, USA) and buffer consisting of
10 mM Tris–HCl, pH7.5, 0.5 mM ethylenediaminetetraacetic acid ,
4% glycerol, 50 mM NaCl, and 0.5 mM dithiothreitol in a total volume
of 9 μl at 4 °C for 10 min. The radiolabeled probe (1 μl) was added and
incubated for 30 min at 25 °C. In the binding competition assay, spe-
ciﬁc bindings of radio-labeled (hot) wild type HRE1 oligonucleotides
probe (WT-HRE1) (TTGCT GCGTG CTTGA TACTT GTTC) to the protein
complexes containing HIF-1αwere monitored by adding an excess of
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cess), a cold mutated HRE1 probe-1 (MT1-HRE1) (TTGCT TTTTG
CTTGA TACTT GTTC) (X25 or X50), a cold another second mutated
HRE1 probe-2 (MT2-HRE1) (TTGCT GCATA CTTGA TACTT GTTC)
(X25 or X50), a cold wild type HRE2 probe (WT-HRE2) (ACAAA
ACGTG TTAAC CCCTT GTGG) (X100) or a cold mutated HRE2 probe
(MT-HRE2) (ACAAA TTTTG TTAAC CCCTT GTGG) (X100). In the bind-
ing inhibition assay using the anti HIF-1α antibody, the antibody spe-
ciﬁcally recognizes a DNA binding domain of HIF-1α. The binding
reactions were pre-incubated with 2 μg of anti HIF-1α antibody
(ab16066, Abcam, Cambridge, UK) for 10 min at 25 °C prior to the ad-
dition of the labeled probe. The reaction mixture was subjected to
electrophoretic separation. The gels were dried and the binding com-
plexes were visualized by a Typhoon 9400 scanner (GE Healthcare,
Life sciences, Uppsala, Sweden).
2.9. Statistical analysis
Statistical signiﬁcance was determined by the Student t-test
(StatView I, Abacus Concepts, Inc., Berkeley, CA) or χ2-test. A P value
of less than 0.05 indicates statistical signiﬁcance.
3. Results
3.1. Down-regulation of hMSH3 is associated with over-expression of
GLUT1 in CRC tissues
In our previous study, we demonstrated that EMAST is common in
primary sporadic CRC [13,14]. Furthermore, loss of hMSH3 expression
in tissue cultured cell lines results in EMAST and MSI-L and there is a
signiﬁcant correlation between EMAST and loss of hMSH3 expression
in CRC tumor tissues [13]. However, loss of hMSH3 expression within
a tumor tissue is largely heterogeneous and could be reversible [13].
During the course of hMSH3 IHC examination of primary CRC tissues,
we have observed that MSH3-negative tumor cells frequently reside
near the necrotic area. Because necrosis in a tumor mass is caused
by hypoxia and because hypoxia down-regulates MMR proteins
[17], we speculate that the observed down-regulation of hMSH3
and its consequence, MSI-L/EMAST, may be caused by hypoxia. To ob-
tain evidence of the connection between hypoxia and down-
regulation of hMSH3, and since over-expression of GLUT1 correlates
with hypoxia [21], we examined the level of GLUT1 expression in 28
cases of sporadic CRC by IHC staining. The hMSH3 expression and
MSI status of these 28 cases had been previously determined [13].
Of 28 CRC tissues examined, 19 CRC tissues over-expressed or were
positive for GLUT1 expression and 9 CRC rarely expressed GLUT1
(Table 1, Supplementary Table 5). The representative IHC staining
for GLUT1 and hMSH3 is shown in Fig. 1. In non-EMAST CRC tissues,
most nuclei were stained positive for MSH3 (Fig. 1A) and there was
no cytoplasmic or membranous staining of GLUT1 in the same tissue
(Fig. 1B). In contrast, a mixture of MSH3-positive and -negative nuclei
was visible in EMAST-positive CRC tissues (Fig. 1C) and over-Table 1
Relationship between expression of GLUT1 and hMSH3.
GLUT1
expressiona
No. of cases with hMSH3 P valued
Negativeb Positivec
+++, ++ 17 2 0.002
+/− 3 6
a +++, ++ represents over expression. +/− represents sporadic or negative
expression.
b Negative when more than 15% of cancer cells are negative for hMSH3 [13].
c Positive when less than 15% of cancer cells are negative for hMSH3 expression [13].
d P value was determined by χ2-test.expression of GLUT1 was detected in the cytoplasm and cell mem-
branes of cancer cells (Fig. 1D). As shown in Table 1, there was a sig-
niﬁcant correlation between over-expression/positive of GLUT1 and
down-regulation of MSH3 in CRC tissues (P=0.002). Likewise over-
expression of GLUT1 was also associated with EMAST in CRC tissues
(Supplementary Tables 4 and 5, P=0.002). These results support
the idea that hypoxia may cause down-regulation of hMSH3, leading
to MSI-L/EMAST.
3.2. Down-regulation of hMSH3 by hypoxia in vitro
We next examined the effect of hypoxia on the expression of
hMSH3 in ten human cancer cell lines derived from different origins.
The changes in hMSH3 expression at the mRNA and protein levels
were monitored 3 days after hypoxia (0.1% O2). We observed three
groups of cell lines that responded differently to hypoxia. In the ﬁrst
group, including HCT116+5, HCT116+3+5 and HEK293, a signiﬁ-
cant reduction in the level of hMSH3 mRNA (~35% of normoxic cells,
Table 2) was observed in cells exposed to hypoxia compared to nor-
moxic cells. Reduction in hMSH3 protein was also observed in
HCT116+5 (40% of normoxic cells, Fig. 2E), HCT116+3+5 (50%,
Supplementary Fig. 1) and HEK293 (66%, Supplementary Fig. 1) at
3 days after hypoxia. In the second group, including colo320DM,
HeLa S3, SW480, SW620, and TGW, moderate levels of down-
regulation in hMSH3 mRNA (~70%, Table 2) and protein (80–90%,
Fig. 2A, Supplementary Fig. 1) were observed by hypoxia. In the
third group, including MCF-7 and GOTO, down-regulation of hMSH3
mRNA (Table 2) and protein (Supplementary Fig. 1) was not detected
during the 3 days of hypoxia. The difference in response to hypoxia
between the ﬁrst and the second group can be explained by the status
of p53, because HCT116+5, HCT116+3+5 and HEK293 contain a
wild type p53 whereas colo320DM, HeLa S3, SW480, SW620, and
TGW contain mutated p53 [27,31].
3.3. p53-Dependent and -independent down-regulation of hMSH3 by
hypoxia
To determine whether p53 status inﬂuenced expression of hMSH3
in response to hypoxia, we ﬁrst measured hMSH3 mRNA levels in
normoxic and hypoxic SW480 transiently expressing exogenously
added wild type p53, and normoxic and hypoxic SW480 that had re-
ceived an empty vector (Supplementary Fig. 3). The results showed
that the presence of wild type p53 in SW480 signiﬁcantly reduced
levels of hMSH3 mRNA in response to hypoxia (Table 3). To further
conﬁrm the role of wild type p53 for down-regulation of hMSH3 by
hypoxia, we constructed p53 knockout HCT116 (null-p53 HCT116)
with wild type hMSH3 (null-p53 HCT116+5) by transferring a nor-
mal human chromosome 5 into null-p53 HCT116 via microcell chro-
mosome transfer (Supplementary Fig. 2). We then compared hMSH3
expression in response to hypoxia between wt-p53 HCT116+5 and
null-p53 HCT116+5. As shown in Table 3, the absence of p53 clearly
reduced the suppressive effect of hypoxia on hMSH3 mRNA. Further-
more, re-introduction of the wild type p53 expression vector into
null-p53 HCT116+5 cells recovered the suppressive effect of hypoxia
on hMSH3 expression (Table 3). p53-dependent down-regulation of
hMSH3 was also observed in protein levels (Fig. 2). A signiﬁcant re-
duction in hMSH3 was observed within 3 days after hypoxia in wt-
p53 HCT116+5 (Fig. 2E and F) but not in mut-p53 SW480 or null-
p53 HCT116+5 (Fig. 2A, B, C and D). Taken together, the above re-
sults indicate that there is a p53-dependent pathway to down-
regulate hMSH3 expression by hypoxia.
When mut-p53 SW480 and null-p53 HCT116 +5 were cultivated
under prolonged hypoxia (0.1% O2, 6 days), signiﬁcant down-
regulation in hMSH3 mRNA (Fig. 3) and protein (Fig. 2A, B, C and D)
was observed in these cells. These results indicate that there is a
p53-independent pathway to down-regulate hMSH3 expression.
Fig. 1. The expression of GLUT1 and hMSH3 in CRC tissues. A: Microsatellite stable CRC tissue positive for nuclear hMSH3 expression. B: Microsatellite stable CRC tissue negative for
cytoplasmic GLUT1 expression. C: An EMAST-positive CRC tissue negative for nuclear hMSH3 expression. D: An EMAST-positive CRC tissue over expressing cytoplasmic GLUT1. Despite
the presence of non-speciﬁc MSH3 signals in the cytoplasm of CRC cells, there was a clear difference between the stained and unstained nucleus by MSH3 IHC (×200, x 630 (insets)).
892 J. Li et al. / Biochimica et Biophysica Acta 1823 (2012) 889–899Although it has been shown that wild type p53 is required for down-
regulation of hMSH2 by short term hypoxia (2 days) [19], it is not
known whether hMSH2 is down-regulated in p53-mutant or -null
cells under prolonged hypoxia. To address this question, null-p53
HCT116+5 and wt-p53 HCT116+5 were treated with 0.1% O2 for 3
and/or 6 days and expressions of hMSH2 were monitored for protein
levels. In wt-p53 HCT116+5, a signiﬁcant decrease in expression of
both hMSH2 and hMSH3 was observed compared to null-p53
HCT116+5 within 3 days after hypoxia (Fig. 2C and D). In contrast,
while the MSH3 protein was signiﬁcantly reduced in null-p53
HCT116 +5 under prolonged hypoxia (6 days), there was no signiﬁ-
cant reduction in hMSH2 protein in the same cells (Fig. 2C and D).
These results conﬁrm the previous observation that down-
regulation of hMSH2 by hypoxia is p53-dependent. Our results fur-
ther demonstrate that down-regulation of hMSH3 can be achieved
through p53-dependent and p53-independent pathways, and that
the latter pathway may be triggered by prolonged hypoxia.Table 2
hMSH3downregulation pattern in hypoxia in human cell lines derived fromvarious origins.
Cell line Origin p53
Status
mRNA
level, %a
Down-
regulation
pattern
Day 1 Day 3
HCT116+5 colorectal cancer wild type 77.2 33.3b * Rapid
HCT116+3+5 colorectal cancer wild type 80.9 41.5* Rapid
HEK293 embryonic kidney wild type ntc 32.6* Rapid
SW480 colorectal cancer mutant 76.9 68.8* Moderate
SW620 colorectal cancer mutant 73.8 75.3b* Moderate
colo320DM colorectal cancer mutant nt 73.8 Moderate
HeLa S3 cervix carcinoma mutant nt 79.4* Moderate
TGW neuroblastoma mutant nt 69.5* Moderate
GOTO neuroblastoma wild type 107.5 96.2 No
MCF-7 breast adenocarcinoma wild type 103.6 100.6 No
*Pb0.05
a Percentage of the relative mRNA amount in hypoxia was determined by the
following formula: Ct at hypoxia/Ct at normoxia×100.
b The mRNA level was determined at day 2 in hypoxia.
c nt: not tested.3.4. Essential promoter regions for transcription of hMSH3
To explore the mechanism by which hypoxia controls the expres-
sion of the hMSH3, we next determined the promoter region(s) es-
sential for transcription of hMSH3 locus using a reporter gene assay.
Six reporter plasmids covering −3102 to +20 relative to the tran-
scription initiation site were constructed (Fig. 4A). Luciferase activity
of each construct was monitored in SW620 and HeLa S3. Reporter
pGL3-MSH3-2658-20 having a region between −2658 and +20
showed the highest luciferase activity. The activity of this construct
in SW620 and HeLa S3 was 3- to 4.7-fold higher than the activity of
the reporter pGL3-MSH3-2480-20 having a region between −2480
and+20 (Fig. 4A). The reporter pGL3-MSH3-3102-20 having a region
between −3102 and +20 showed 78% of the activity of the pGL3-
MSH3-2658-20 and this difference was signiﬁcant (SW620:
P=0.04, HeLa S3: P=0.03). Thus, the results suggest that a binding
site for a repressor protein may exist within the region between
−3102 and −2658. When pGL3-MSH3-2480-20 was tested in both
SW620 and HeLa S3, a signiﬁcant reduction in reporter activity was
observed (Fig. 4A). Similarly, other three reporter constructs missing
the region spanning−2658 to−2480 showed basal activities. These
results indicate that the region between−2658 and−2480 contains
an enhancer element essential for hMSH3 transcription. The core pro-
moter of hMSH3 has an incomplete initiator (Inr: 4/7) and complete
downstream promoter element motifs (DPE: 6/6) at −1 to +6 and
+29 to +34, respectively, which were frequently found in the
TATA-less promoter (Fig. 4C) [32]. The reporter pGL3-MSH3-2658-
20 used in the above experiments contains the Inr motif, but not
the DPE motif. To determine the role of the DPE motif in hMSH3 tran-
scriptional activity, we constructed pGL3-MSH3-681-50 and pGL3-
MSH3-2658-50, each containing the DPE motif, and compared their
reporter activities with those of pGL3-MSH3-681-20 and pGL3-
2658-20. As shown in Fig. 4B, the two constructs containing DPE
showed higher activity than the construct without DPE, indicating
that DPE contributes to the enhancement of transcriptional activity.
Thus, two regions, −2658 to −2480, and the core promoter region,
−30 to +50, were identiﬁed as essential regions for transcription
of the hMSH3.
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Fig. 2. p53-dependent and p53-independent down-regulation of hMSH3 and hMSH2 proteins. A: hMSH3 expressed by normoxic and hypoxic mut-p53 SW480 cells. B: hMSH2
expressed by normoxic and hypoxic mut-p53 SW480 cells C: hMSH3 expressed by normoxic and hypoxic null-p53 HCT116+5 cells. D: hMSH2 expressed by normoxic and hypoxic
null-p53 HCT116+5 cells. E: hMSH3 expressed by normoxic and hypoxic wt-p53 HCT116+5 cells. F: hMSH2 expressed by normoxic and hypoxic wt-p53 HCT116+5 cells. A
signiﬁcant reduction in hMSH3 and hMSH2 proteins was observed within 3 days after hypoxia in cells with wt-p53 but not in cells with null- or mut-p53. A signiﬁcant reduction
in hMSH3 but not in hMSH2 was observed in cells with null- or mut-p53 at 6 days after hypoxia.
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region of hMSH3 for down-regulation of hMSH3 by hypoxia
We next mapped a promoter sub-region that can control tran-
scription of hMSH3 under hypoxia. When a reporter plasmid covering
−2658 to +50 of hMSH3 was introduced into hypoxic and normoxic
cells (mut-p53 SW620 and wt-p53 HCT116 +5), reporter activity
was signiﬁcantly reduced in hypoxic cells regardless of p53 status. Be-
cause a consensus sequence for HREs was present in two sites at
−2525 to −2521 and −1639 to −1635 (Fig. 5A), we next deter-
mined whether these sequences played a role for hypoxia-induced
repression of hMSH3. While the construct having two putative HREs
(−2658 to +20) and the construct having one HRE (−2480 to
+20) showed reduced reporter activity in hypoxic cells (Fig. 5B),
the shorter construct (−1267 to +20) lacking the two HRE sitesTable 3
p53-dependent down-regulation of hMSH3 mRNA by hypoxia.
Cell p53 Status Reduction of
hMSH3 mRNA, %
P value
SW480+pCEP4 mutant 51.8 0.003
SW480+pXZ53 mutant+wild type 64.8
HCT116+5 wild type 66.8 0.01
null-p53 HCT116+5 null 32.7
null-p53 HCT116+5 null 40.0 0.007
+ pCEP4
null-p53 HCT116+5 null+wild type 57.0
+ pXZ53
The hMSH3 mRNA was quantiﬁed by qRT-PCR. P values were determined by Student
t-test.did not respond to hypoxia. Furthermore, the constructs with mutat-
ed HREs also did not show reduction in reporter activity by hypoxia
(Fig. 5C). These results indicate that down-regulation of hMSH3 by
hypoxia is partly mediated through putative HRE sites within a pro-
moter region of the hMSH3.
3.6. Involvement of HIF-1α in down-regulation of hMSH3 by hypoxia
As shown above, the putative HRE sites within the hMSH3 promot-
er region are involved in hypoxia-induced repression of hMSH30 2 4 6R
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similar levels of reduction in hMSH3 mRNA was observed after 6 days of hypoxia in
null- or mut-p53 cells compared to wt-p53 cells.
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to HRE sites, we examined the effect of HIF-1α knockdown by siRNA
on down-regulation of hMSH3 by hypoxia. The levels of HIF-1α in wt-
p53 HCT116+5 and mut-p53 SW620 reached their maximum at
1 day after hypoxia and became undetectable by 3 days after hypoxia
(Fig. 6A). When siRNA speciﬁc to HIF-1αwas introduced into HCT116
+5 and SW620, a 78% reduction in the hypoxia-induced HIF-1α pro-
tein was observed within 1 day in cells treated with HIF-1α-speciﬁc
siRNA as compared to hypoxic cells treated with control siRNA
(Fig. 6B). Under these conditions, a signiﬁcant difference in down-
regulation of hMSH3 mRNA was observed between hypoxic wt-p53
HCT116+5 cells treated with HIF-1α speciﬁc siRNA and control
siRNA (Fig. 6C, P=0.0258). Similarly, a signiﬁcant difference was ob-
served between hypoxic mut-p53 SW620 treated with HIF-1α specif-
ic siRNA and control siRNA at 1 day after hypoxia (Fig. 6C, P=0.046).
Down-regulation of hMSH3 protein by hypoxia was also inhibited by
HIF-1α siRNA in both cell lines (Fig. 6D).
We next determined whether HIF-1α directly binds to the puta-
tive HREs in the hMSH3 promoter by EMSA and binding inhibition
assay using anti HIF-1α antibody speciﬁcally recognizes a DNA bind-
ing domain of HIF-1α (see Materials and methods). When the nuclear
extracts from normoxic and hypoxic wt-p53 HCT116+5 cells were
mixed with a radio-labeled (hot) wild type HRE1 probe (WT-HRE1),
at least 5 species of proteins that bind to WT-HRE1 probe were in-
duced by hypoxia (Fig. 7A). Two of them indicated as “a” and “b”
were speciﬁcally diminished by anti HIF-1α antibody, indicatingthat “a” and “b” contain HIF-1α and bind to WT-HRE1 probe
(Fig. 7A). These bindings were inhibited when an excess of non-
radio-labeled (cold) WT-HRE1 oligonucleotides (WT-HRE1) was
added to the reaction (Fig. 7A). In contrast, an excess of cold mutated
oligonucleotides whose sequences were the same as the WT-HRE1
probe except the HRE1 site was replaced by mutated sequences,
TTTTG, (MT1-HRE1) did not compete with hot WT-HRE1 probe. How-
ever, when another cold oligonucleotide whose sequences were the
same as WT-HRE1 probe except that the HRE1 site was replaced by
mutated sequences, GCATA, (MT2-HRE1) competed with hot WT-
HRE1 for formation of band “a” but not that of band “b” (Fig. 7B). Fur-
thermore, an excess of cold oligonucleotides containing the HRE2 re-
gion of the hMSH3 (WT-HRE2) but not the oligonucleotides
containing mutated HRE2 site (MT-HRE2, TTTTG) inhibited the bind-
ing of WT-HRE1 probe to form bands “a” and “b” (Fig. 7C). Taken to-
gether, in hypoxic wt-p53 HCT116+5, 1) there were two forms of
HIF-1α complexes, A and B, and they speciﬁcally bound to the HRE1
site of the WT-HRE1 probe, 2) complex A has a larger mass than the
complex B, and the amount of its binding product with probe WT-
HRE1, “a”, is less than the amount of a binding product formed be-
tween the complex B and probeWT-HRE1, “b”, 3) there is a difference
in binding speciﬁcity between complexes A and B; A but not B binds
to MT2-HRE1, and 4) both complexes A and B not only speciﬁcally
bind to the HRE1 site but also to the HRE2 site (Fig. 7C). To conﬁrm
complexes A and B speciﬁcally bind to the HRE2 sites, hot-WT-HRE2
probe was mixed with hypoxic wt-p53 HCT116+5 nuclear extracts.
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Fig. 5. The role of the putative HRE in down-regulation of reporter activity by hypoxia.
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MSH3-2480-20 and pGL3-MS3-1267-20. After transfection, cells were cultured for an-
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of mutations in HRE on reporter activity in response to hypoxia. Three reporter plas-
mids having mutations at HRE1, at HRE2, and at both HRE1 and HRE2, designated as
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detected in hypoxic cells and these bands were diminished by anti
HIF-1α antibody and a cold WT-HRE2 probe but not by a cold MT-
HRE2 probe (Supplementary Fig. 4A and 4B). These results conﬁrm
that complexes A and B speciﬁcally bind to the HRE2 sites.
When the experiments described above were repeated using cell
extracts from hypoxic mut-p53 SW620, two complexes A and B
were also detected (Fig. 7D–F and Supplementary Fig. 4C and 4D).
However, the binding of A to the HRE1 (Fig. 7D–F) and HRE2 (Supple-
mentary Fig. 4C and 4D) in hypoxic mut-p53 SW620 dominated over
that of B, whereas the binding of B to the HREs (Fig. 7A–C and Supple-
mentary Fig. 4A and B) dominated over that of A in wt-p53 HCT116
+5. Because of this sharp contrast in the binding proﬁles of A and B
between wt-p53 and mut-p53 cells, we performed EMSA using cell
extracts from null-p53 HCT116+5 cells to examine whether thestatus of p53 may effect the binding proﬁle of complexes A and B.
As shown in Fig. 8, in contrast to the results obtained from wt-p53
counterparts, the intensity of bands “a” in the HRE1 site (Fig. 8A)
and the intensity of band c in the HRE2 site (Fig. 8B) became stronger
in null-p53 cells. These results support the idea that p53 status may
inﬂuence the binding of complexes A and B to HRE sites.
4. Discussion
In this study, we showed that there is a signiﬁcant association be-
tween over-expression of the hypoxic marker GLUT1 and down-
regulation of hMSH3 (Table 1). A signiﬁcant association between
over-expression of GLUT1 and EMAST in CRC tissues was also ob-
served (Supplementary Table 4). These results support the idea that
hypoxia may down-regulate hMSH3, which may result in MSI-L/
EMAST in CRC tissues.
We therefore aimed to obtain direct evidence that hypoxia down-
regulates hMSH3 expression in vitro using 10 human tissue-cultured
cell lines. This analysis clariﬁed that there are at least three different
modes of hMSH3 expression in response to hypoxia. First is the
p53-dependent mode of regulation in which the rate of down-
regulation in MSH3 was rapid at both mRNA and protein levels. Sec-
ond is the p53-independent mode of regulation that occurred under
prolonged hypoxia (6 days) and at slower rate in cells with mutated
or null p53 (Fig. 2). Third is case where there was no down-
regulation of MSH3 in response to hypoxia after either a short or pro-
longed period of hypoxia. This type of response was observed in two
cell lines with wt-p53, MCF-7 and GOTO (Table 2). Because we
detected stabilization of HIF-1α and down-regulation of hMSH2 in
MCF-7 cells within 24 hr after hypoxia, this cell line has an intact
pathway to down-regulate hMSH2. It remains to be determined
why these cell lines lack responsiveness to hypoxia for down-
regulation of hMSH3. In contrast to hMSH3, no signiﬁcant down-
regulation of hMSH2 occurred in cells with null/mut-p53 cells under
both short and prolonged hypoxia. The results indicate that hMSH2
and hMSH3 loci respond differently to hypoxia.
The above results suggest that the status of p53 has a major im-
pact on the hypoxic response of MSH3 expression in CRC tissues. It
is interesting to note that the EMAST phenotype that is a consequence
of hMSH3-deﬁciency is signiﬁcantly associated with mut-p53 in
NSCLC [7]. As shown in this paper, hMSH3 can be down-regulated
in cells with wt-p53 and with null/mut-p53 by hypoxia. However, it
could be that hypoxic cells with mut-p53 have greater capacity to
multiply their DNA under depressed MSH3 compared to hypoxic
cells with wt-p53 [33]. This could explain why EMAST tumors have
a high frequency of p53 mutations in NSCLC. To test whether this is
the case in CRC, we analyzed the LOH status of 3 polymorphic
markers within the TP53 locus in our 26 cases of primary CRC. Our
preliminary data indicates that 65% (13 of 20 cases) of EMAST CRC
and 33.3% (2 of 6 cases) of non-EMAST CRC showed LOH at least
one of three markers examined (Supplementary Table 4). However,
although there was a trend for association between LOH at TP53
locus and EMAST, it was not statistically signiﬁcant (P=0.169). A fur-
ther study that can detect mutations in TP53 by direct sequencing
using a larger cohort is necessary to clarify this matter.
In this study, we isolated the promoter region of the hMSH3 to
identify critical sequences that may affect hMSH3 transcription in re-
sponse to hypoxia. By reporter gene assays, we identiﬁed two puta-
tive HREs sequences, whose deletions or mutations resulted in loss
of responsiveness of the reporter constructs to hypoxia in a cell
lines with wt-p53 and mut-p53 cell lines (Fig. 5). These results sug-
gest that down-regulation of hMSH3 by hypoxia is mediated through
the binding of some transcription factor at these HRE sites.
Since HIF-1α is a strong candidate for such a factor, we investigat-
ed whether HIF-1α mediates down-regulation of hMSH3 by hypoxia.
First, a knockdown of HIF-1α resulted in a signiﬁcant loss of
BA
C D
Fig. 6. Role of HIF-1α for down-regulation of hMSH3 by hypoxia. A: Stabilization of the HIF-1α protein in SW620 and HCT116+5 cells by hypoxia. Cells were cultured for 0, 1, 2, and
3 days in hypoxia and the amount of HIF-1αwas monitored by Western blot analysis with anti HIF-1α antibody. α-Tubulin was used as a loading control. B: HIF-1α knockdown by
siRNA. Cells were transfected with a negative control (ctr) oligomer or an HIF-1α siRNA (HIF) oligomer and cultured under hypoxia for the indicated days. The amount of HIF-1α
was compared between hypoxic cells transfected with a negative control (ctr) oligomer and the HIF-1α siRNA (HIF) oligomer after normalization by α-tubulin signals. C: Effect of
HIF-1α knockdown on hypoxia-induced down-regulation of hMSH3 mRNA. HCT116+5 and SW620 transfected with a negative control (ctr) oligomer (open bars) and an HIF-1α
speciﬁc siRNA oligomer (closed bars) were cultured in hypoxia for the indicated number of days. The amount of hMSH3mRNA was compared between the cells transfected with ctr
and HIF siRNA. *, Pb0.01; **, Pb0.05. D: Effect of HIF-1α knockdown on hypoxia-induced down-regulation of hMSH3 protein. HCT116+5 and SW620 transfected with a negative
control (ctr) oligomer (open bars) and an HIF-1α speciﬁc siRNA oligomer (closed bars) were cultured in hypoxia for the indicated number of days. The amount of hMSH3 was
compared between hypoxic cells transfected with a negative control (ctr) oligomer and the HIF-1α siRNA (HIF) oligomer after normalization by α-tubulin signals.
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(Fig. 6A–D). Second, the EMSA showed that there are two different
forms of the protein complexes containing HIF-1α, A and B, induced
in both hypoxic wt-p53 HCT116+5 and in mut-p53 SW620, speciﬁ-
cally bind to putative HRE1 and HRE2 sites (Fig. 7A–F). Furthermore,
our results suggest that complex A occupies the HRE1 and the HRE2
sites in null/mut-p53 cells more predominately than does complex
B, whereas complex B occupies both HREs in wt-p53 cells more pre-
dominately than does complex A. It remains to be determined wheth-
er an exact correlation exists between the binding proﬁles of A and B,
and p53 status in general.
In our preliminary experiments, biochemical hypoxia induced by
desferrioxamine mesylate or cobalt failed to down-regulate hMSH3
in HCT116+5 and SW480, even though stabilization of HIF-1α oc-
curred in treated cells. These results suggest that some factor(s) in
addition to HIF-1α by hypoxia is required for down-regulation of
hMSH3. Further experiments are necessary to clarify the identities of
the protein complexes containing HIF-1α, A and B, as well as an addi-
tional transcription factor that interacts with HIF-1α, to clarify their
relationships to p53 status and to down-regulation of hMSH3
transcription.
It has been proposed by Koshiji et al. that expression of hMSH2 in
normoxic cells is mediated by binding of a complex between SP1 and
MYC/MAX to the GC box of the promoter region at this locus, but that
in hypoxic cells, HIF-1α replaces MYC/MAX to form a complex with
SP1 in a p53-dependent manner, leading to down-regulation of
hMSH2 expression in wt-p53 hypoxic cells [19]. Our preliminaryexperiments showed that knockdown of c-myc by siRNA (> 90% re-
duction in c-myc mRNA compared to control) in HCT116+5 and
SW620 did not reduce hMSH3 expression, suggesting that interaction
between HIF-1α and SP1, which displaces MYC/MAX from a gene
promoter, may not be essential for hMSH3 down-regulation by hyp-
oxia. On the other hand, direct interaction between HIF-1α and
HREs at the promoter regions of hMSH2 has not been explored even
though at least four putative HREs exist at the promoter region of
this gene. Thus, it would be interesting to determine whether HIF-
1α complex B, that predominantly binds to the hMSH3 HREs in wt-
p53 cells, selectively interacts with HREs of the hMSH2 locus while
complex A does not, and whether this interaction also plays a role
for down-regulation of hMSH2 by hypoxia.
Finally, what is a pathobiological signiﬁcance of hypoxia-induced
down-regulation of hMSH3 on CRC carcinogenesis? Several studies
have demonstrated that hypoxia enhances the aggressiveness of can-
cer and promotes the metastatic potential of primary tumor tissues
[34–38]. Therefore, depressed hMSH3 may not only induce MSI-L
and/or EMAST but may also induce frame-shift mutations at the
intra-genic microsatellite present in a putative target gene in hypoxic
CRC cells. Such a mutated gene may contribute to the progression of
CRC. Alternatively, the down-regulation of hMSH3 and its consequent
MSI-L and/or EMAST may merely be a byproduct of hypoxia and have
little effect on the progression of CRC. In either case, the MSI-L and/or
EMAST phenotype in primary CRC may be signiﬁcantly associated
with the metastatic potential of these tumors. In support of this
idea, the MSI-L exhibited by Dukes' C primary CRC is associated
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897J. Li et al. / Biochimica et Biophysica Acta 1823 (2012) 889–899with a poor prognosis [39]. Based on this assumption, we are current-
ly examining the relationship between recurrent metastasis and MSI-
L/EMAST in sporadic primary CRCs.
5. Conclusion
Over-expression of GLUT1 is associated with down-regulation of
hMSH3 and with MSI-L/EMAST in CRC tissues. Hypoxia induces
down-regulation of hMSH3 expression in human cancer cell linesthrough p53-dependent and p53-independent mechanisms. HIF-1α
stabilized by hypoxia is involved in suppressing hMSH3 transcription
through HREs sites within the 5′ promoter region of hMSH3 in both
p53-dependent and p53-independent pathways.
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